Group 1: Financial Performance - The company achieved operating revenue of 228 million yuan, representing a year-on-year growth of 11.73% [2] - The net profit attributable to shareholders reached 72.61 million yuan, with a year-on-year increase of 23.39% [2] - The net profit after deducting non-recurring gains and losses was 66.06 million yuan, showing a year-on-year growth of 32.81% [2] - Research and development investment amounted to 26.42 million yuan, accounting for 11.57% of the operating revenue [2] - As of June 30, 2024, total assets were 1.539 billion yuan, and net assets attributable to shareholders were 1.345 billion yuan [2] Group 2: Industry Context and Competitive Landscape - The overall industry remains competitive, with the company launching new products in the first quarter to address the competitive environment [3] - The company has established a supplier access system to ensure a stable supply chain and has built strategic partnerships with reputable upstream suppliers [3] - Cost control measures include maintaining mutually beneficial relationships with suppliers and strict budget management [3] Group 3: Market Insights and Future Outlook - The estimated consultation rate for pelvic floor treatment is currently at 13.4%, based on assumptions regarding the use of disposable electrodes [4] - Differences in data estimates arise from varying calculation bases and assumptions regarding the target populations for disposable electrode screenings [4] - The company emphasizes that the provided estimates are for reference and understanding, not commitments to future performance [4] Group 4: Risk Warning - Investors are advised to be cautious regarding investment risks, as the information provided does not constitute commitments or guarantees from the company regarding industry or performance forecasts [4]

证券代码：688273 证券简称：麦澜德 公告编号：2024-058 南京麦澜德医疗科技股份有限公司 关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 9 月 23 日 上午 9:00-10:00 （二） 会议召开地点：上证路演中心 重要内容提示： 会议召开时间：2024 年 9 月 23 日(星期一) 上午 9:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 9 月 12 日(星期四)至 9 月 20 日(星期五)16:00 前登录上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 （mld@medlander.com）进行提问。公司将在说明会上对投资者普遍关注的问题 ...

Financial Performance - The company achieved operating revenue of 228 million CNY in the first half of 2024, representing a year-on-year increase of 11.73% [1] - The net profit attributable to shareholders reached 72.61 million CNY, up 23.39% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 66.06 million CNY, reflecting a growth of 32.81% [2] - R&D investment amounted to 26.42 million CNY, accounting for 11.57% of the operating revenue [2] - As of June 30, 2024, total assets were 1.539 billion CNY, with net assets attributable to shareholders at 1.345 billion CNY [2] Market Trends and Product Development - The company is focusing on pelvic floor and gynecological rehabilitation products, with the "Magnetoelectric Thermal Imaging · Smart Integration PI-ONE" system launched in March 2024 [2] - There is a growing demand for pelvic floor dysfunction (PFD) treatment, with increasing awareness and screening in primary healthcare settings [3] - The company is expanding its marketing strategy to reach secondary and primary hospitals, community health institutions, and clinics to enhance PFD screening [3] Strategic Planning - The company plans to adopt a dual strategy of "independent R&D + external expansion" to enhance its reproductive health and anti-aging product lines [4] - The sales model is primarily distribution-based, with direct sales supplementing in non-medical markets [5] - Future development in the sports rehabilitation sector will be approached with caution, observing market opportunities before significant investment [5] Risk Management - The company emphasizes that any forecasts regarding industry trends or strategic plans should not be interpreted as commitments or guarantees of performance [5]

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024 年半年度持续督导跟踪报告 2022 年 8 月 11 日，南京麦澜德医疗科技股份有限公司（以下简称"麦澜德" 或"公司"）在上海证券交易所科创板上市。根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等相关规定，南京证券股份有限公司 （以下简称"南京证券"、"保荐机构"）作为麦澜德的保荐机构，对麦澜德进行持 续督导，持续督导期为 2022 年 8 月 11 日至 2025 年 12 月 31 日。 2024 年 1-6 月，南京证券对麦澜德的持续督导工作情况如下： | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针对 具体的持续督导工作制定相应的工作计划 | 保荐机构已建立并有效执行了持 续督导制度，并制定了相应的工 | | | | 作计划 | | | 根据中国证监会相关规定，在持续督导工作开始 前，与上市公司或相关当事人签署持续督导协 | 保荐机构已与麦澜德签订保荐协 议，该协议明确了双方在持续督 | | 2 | | | | | ...

证券代码：688273 证券简称：麦澜德 公告编号：2024-057 南京麦澜德医疗科技股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 30 | | --- | --- | | 普通股股东人数 | 30 | | 2、出席会议的股东所持有的表决权数量 | 66,447,957 | | 普通股股东所持有表决权数量 | 66,447,957 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 67.9010 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 67.9010 | | （%） | | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 （一） 股东大会召开的时间：2024 年 09 月 06 日 （二） 股东大会召开的地点：南京市雨花台区凤展路 32 号 A2 栋北公司会议室 1、本次会议 ...

北京市中伦律师事务所 关于南京麦澜德医疗科技股份有限公司 2024 年第三次临时股东大会的 法律意见书 致：南京麦澜德医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》及中国证券监督管理委员会发布的《上市公司股东大会规则》等 规定，北京市中伦律师事务所（以下简称"本所"）接受南京麦澜德医疗科技股 份有限公司（以下简称"公司"）的委托，指派本所律师对公司 2024 年第三次 临时股东大会（以下简称"本次股东大会"）进行见证并就相关事项出具本法律 意见书。 本法律意见书仅就本次股东大会的召集人资格、召集和召开程序、出席本次 股东大会人员的资格、会议表决程序是否符合法律、法规、规范性文件及《公司 章程》的规定以及表决结果是否合法有效发表意见，而不对本次股东大会所审议 的议案内容以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发 表意见。 为出具本法律意见书，本所律师列席了本次股东大会，并根据有关法律、法 1 法律意见书 规、规范性文件的规定和要求，按照律师行业公认的业务标准、道德规范和勤勉 尽责精神，对公司提供的与本次股东大会有关的文件和事实进行了核查 ...

证券代码：688273 证券简称：麦澜德 公告编号：2024-056 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务，敬 请广大投资者注意投资风险。 站（www.sse.com.cm）披露的《关于以集中竞价交易方式回购股份的回购报告书》 （公告编号：2024-041）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： 2024 年 8 月，公司未通过集中竞价交易方式回购股份。 截至 2024 年 8 月 30 日，公司通过上海证 ...

证券代码：688273 证券简称：麦澜德 公告编号：2024-050 南京麦澜德医疗科技股份有限公司 2024 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、上海证券交易所《上海证券交易所科创板上市公司 自律监管指引第 1 号——规范运作》等有关规定，南京麦澜德医疗科技股份有限 公司（以下简称"公司"或"本公司"）董事会编制了 2024 年半年度（以下简称"报告 期内"）募集资金存放与实际使用情况的专项报告如下： 一、募集资金基本情况 （一）实际募集资金金额及资金到账情况 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2022〕1189 号），公司获准向 社会公众公开发行人民币普通股（A 股）2,500 万股，每股面值为人民币 1 元，每 股发行价格为人民币 40.29 元，募集资金总额为人民币 100,725 ...

重要内容提示： 证券代码：688273 证券简称：麦澜德 公告编号：2024-051 南京麦澜德医疗科技股份有限公司 关于 2024 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京麦澜德医疗科技股份有限公司（以下简称"公司"）2024 年半年度归属 于上市公司股东的净利润为 72,606,695.07 元，截至 2024 年 6 月 30 日，母公司可 供分配利润为 173,787,040.41 元，上述财务数据未经审计。经董事会决议，公司 2024 年半年度拟以实施权益分派股权登记日登记的总股本扣除公司回购专用证券 账户中的股份数为基数分配利润，本次利润分配的方案如下：公司拟向全体股东每 10 股派发现金红利人民币 4.00 元（含税）。截至本公告披露日，公司总股本为 100,000,000 股，扣减回购专用证券账户中的 2,140,000 股，参与分红的股份总数为 97,860,000 股，以此计算合计拟派发现金红利 39,144,000.00 元（含税）。公司不进 行公积金转增股本， ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥228,384,180.04, representing an increase of 11.73% compared to ¥204,401,110.46 in the same period last year[19]. - The net profit attributable to shareholders for the same period was ¥72,606,695.07, up 23.39% from ¥58,842,942.52 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was ¥66,059,033.24, reflecting a 32.81% increase from ¥49,740,712.28 in the previous year[19]. - The basic earnings per share for the first half of 2024 was ¥0.7331, a 24.97% increase compared to ¥0.5866 in the same period last year[20]. - The weighted average return on equity increased to 5.29%, up by 1.01 percentage points from 4.28% year-on-year[20]. - The net profit for the first half of 2024 was ¥75,911,425.54, representing a 25.1% increase from ¥60,663,627.99 in the previous year[150]. - The total comprehensive income for the first half of 2024 was ¥75,911,425.54, compared to ¥60,663,627.99 in the same period of 2023[151]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 RMB per 10 shares, totaling 39,144,000 RMB, which accounts for 53.91% of the net profit attributable to shareholders for the first half of 2024[5]. - The company plans to distribute dividends totaling ¥59,334,000.00 during the first half of 2024[162]. Research and Development - Research and development expenses accounted for 11.57% of operating revenue, a decrease of 2.52 percentage points from 14.09% in the previous year[20]. - Total R&D investment amounted to ¥26,417,883.33, a decrease of 8.29% compared to the previous year, with R&D investment accounting for 11.57% of operating revenue, down 2.52 percentage points[47]. - The company has achieved 37 domestic invention patents and 1 international invention patent, along with 110 utility model patents and 68 design patents as of June 30, 2024[45]. - The company has developed a pelvic floor rehabilitation electrophysiology technology platform, achieving higher frequency and more waveform combinations for personalized treatment[35]. - The company is actively exploring next-generation electrophysiology technologies to enhance market competitiveness[35]. Market Position and Strategy - The company operates in the pelvic floor and obstetric rehabilitation medical device sector, focusing on R&D, production, sales, and services, with a diverse product line including biofeedback devices and ultrasound systems[24]. - The company’s main sales strategy is based on a "distribution-first, direct sales-second" model, with annual agreements and a buyout sales approach for long-term partners[25]. - The company is positioned in a rapidly growing industry, supported by increasing public awareness and government policies favoring rehabilitation medical devices[28]. - The company has established a marketing network with over 1,100 distributors, covering more than 14,000 institutions nationwide[68]. Operational Risks and Governance - The board of directors and management confirm the accuracy and completeness of the financial report, ensuring no significant omissions or misleading statements[2]. - The company has outlined various operational risks and corresponding mitigation measures in the report[3]. - The company does not have any special arrangements for corporate governance[8]. - The company has not violated decision-making procedures for external guarantees[8]. - There are no non-operational fund occupations by controlling shareholders or related parties[7]. Financial Position - The total assets at the end of the reporting period were ¥1,538,820,898.97, a slight increase of 0.32% from ¥1,533,923,915.26 at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,345,303,841.03, showing a minor decrease of 0.04% from ¥1,345,778,874.02 at the end of the previous year[19]. - The total liabilities decreased slightly to ¥156,772,033.49 from ¥158,603,955.36, a reduction of 1.0%[145]. - The company's cash and cash equivalents were CNY 815,031,075.77, a decrease of 9.3% from CNY 899,001,714.20[146]. Compliance and Regulatory Matters - The company has established a commitment to ensure that no interests are unfairly transferred to other entities or individuals[117]. - The company will publicly disclose any failure to comply with shareholding commitments, maintaining accountability[107]. - The company has pledged to maintain the accuracy and completeness of its prospectus and other disclosure materials, accepting legal responsibility for any misleading statements[118]. - The company is closely monitoring macroeconomic risks, including economic cycle adjustments and global trade tensions, and is preparing response plans[79]. Social Responsibility - The company actively participates in medical poverty alleviation and public welfare activities, aligning with social responsibility initiatives[74]. - The company donated medical supplies valued at 1 million yuan to support grassroots hospitals in women's health screenings and treatments[100].